• 약학회지
• /
• 제29권2호
• /
• pp.90-95
• /
• 1985

The development of radioimmunoassay (RIA) for high-density lipoprotein (HDL) in Japanese quail serum will contribute to the screening of drugs acting on cholesterol transport. We have developed a double antibody RIA method for J. quail HDL. The first antibody was raised in rabbit by immunization of HDL isolated by the dextrane sulfate-$Mn^{#}$ precipitation method. For the preparation of raclioiodinated antigen, HDL was further purified by combination of electrophoretic procedure. Using the second antibody raised in goat by rabbit IgG, we have furnished the RIA method for HDL. It showed high specificity and sensitivity of working assay range, 0.1-33.mu.g HDL/tube. There was no correlation between the radioimmunoassay of HDL and the enzyme assay of HDL-cholesterol.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1973년도 제12차 학술대회
• /
• pp.63.1-63.1
• /
• 1973

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1978년도 제17차 학술대회
• /
• pp.54.1-54.1
• /
• 1978

• 대한방사성의약품학회지
• /
• 제8권2호
• /
• pp.95-101
• /
• 2022

Microfluidic radioimmunoassay (RIA) platform called µ-RIA spends less reagent and shorter reaction time for the analysis compared to the conventional tube-based radioimmunoassay. This study reported the design of µ-RIA chips optimized for the gamma counter which could measure the small samples of radioactive materials automatically. Compared with the previous study, the µ-RIA chips developed in this study were designed to be compatible with conventional RIA test tubes. And, the automatic gamma counter could detect radioactivity from the ¹²⁵I labeled anti-PSA attached to the chips. Effects of the multi-layer microchannels and two-phase flow in the µ-RIA chips were investigated in this study. The measured radioactivity from the ¹²⁵I labeled anti-PSA was linearly proportional to the number of stacked chips, representing that the radioactivity in µ-RIA platform could be amplified by designing the chips with multi-layers. In addition, we designed µ-RIA chip to generate liquid-gas plug flow inside the microfluidic channel. The plug flow can promote binding of the biomolecules onto the microfluidic channel surface with recirculation in the liquid phase. The ratio of liquid slug and air slug length was 1 : 1 when the ¹²⁵I labeled anti-PSA and the air were injected at 1 and 35 µL/min, respectively, exhibiting 1.6 times higher biomolecule attachment compared to the microfluidic chip without the air injection. This experimental result indicated that the biomolecular reaction was improved by generating liquid-gas slugs inside the microfluidic channel. In this study, we presented a novel µ-RIA chips that is compatible with the conventional gamma counter with automated sampler. Therefore, high-throughput radioimmunoassay can be carried out by the automatic measurement of radioactivity with reduced radiowaste generation. We expect the µ-RIA platform can successfully replace conventional tube-based radioimmunoassay in the future.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1969년도 제8차 학술대회
• /
• pp.6.2-6.2
• /
• 1969

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1973년도 제12차 학술대회
• /
• pp.49.1-49.1
• /
• 1973

• 대한방사선기술학회지:방사선기술과학
• /
• 제5권1호
• /
• pp.55-62
• /
• 1982

Measurement of triiodothyronine($T_3$) concentration is useful for the diagnosic and treatment of thyroid gland diseases. Fundermental studies of measurement of $T_3$ concentration by radioimmunoassay were performed and values determined by commercially available kit, Coat-A-Count, Diagnostic Products Corporation. The optimal utilization of the radioimmunoassay in measuring $T_3$ concentrations is dependant not only on high quality performance of the assay, but also on their appropriate application to the clinical situation. These are several aspects that must be considered in every individual case. These include factors such as accurate pippeting in reagent preparation in the assay and through decanting to remove all visible moisture after incubation steps and so forth. In attempt to assess quality control of the radioimmunoassay of serum $T_3$, serum pools with high, medium, low $T_3$ concentrations were assayed for each of 5 samples. The results obtained with this study were as follow: 1. The coefficient of variation(C. V.) for the standard curve ranged between $0.2{\sim}3.5%$. 2. It was necessary that both incubation time and temperature should correctly be maintained all the in the assay performance. 3. The precison with the $T_3$ RIA procedure was good. 4. The measured values of serially diluted serum $T_3$ concentration with Ong/dl standard solution was proportional to the predicted values. However dilution curve of distilled water was not strait. 5. Calculated $T_3$ values of patient serum in normal group was $107.8{\pm}25.90ng/dl$ in male patient and $127.29{\pm}24.08ng/dl$ in female patient.

• The Korean Journal of Physiology
• /
• 제28권1호
• /
• pp.91-97
• /
• 1994

In order to produce a specific bombesin antiserum far very sensitive radioimmunoassay, synthetic $[lys^3]-bombesin$ conjugated to bovine serum albumin was subcutaneously injected into guinea pigs. The conjugation was performed using either carbodiimide or gIutaraldehyde as a coupling agent. The antisera were characterized by analysis of Scatchard and Sips plots. The antiserum LBE 2G/2 raised by repeat injection of the immunogen conjugated with carbodiimide showed the titer of 1 : 188,000, very low cross-reactivity to bombesin-like peptides except bombesin, with high affinity constant $(1.64{\times}10^{11}\;M^{-1})$ and high heterogeneity index (0.91). The antiserum LBG 1G/2 produced by repeat injection of the immunogen conjugated with glutaraldehyde possessed the titer of 1 : 43,000, high cross-reactivity to some bombesin-like peptides, high affinity constant $(1.19{\times}10^{11}\;M^{-1})$ and high heterogeneity index (0.79). These results indicate that the antiserum LBE 2G/2 is specific only to bombesin and that the antiserum LBG IG/2 binds to some bombesin-like peptides such as alytesin, gastrin releasing peptide and neuromedin C. The antiserum LBE 2G/2 is sufficient for the very sensitive radioimmunoassay of bombesin.

• 핵의학기술
• /
• 제16권1호
• /
• pp.108-114
• /
• 2012

면역측정법을 이용하는 검사실에서 가장 많이 사용하고 있는 상업용 제3자 정도관리물질이 BIO-RAD사에서 제공하는 물질이다. 현재 BIO-RAD 정도관리 물질에 포함된 Reference Sheet에는 비방사면역측정을 이용한 검사방법과 검사장비별로 각 측정물질의 Acceptable Range가 기재되어 있다. 그러나 방사면역측정법을 이용하여 검사하는 측정kit나 기기에 대해서는 실무에 적용할 만한 Acceptable Range에 대한 언급이 다소 부족한 것이 현실이다. 방사면역측정검사에 대한 Acceptable Range를 설정하여 검사결과의 객관성을 높이고 누적된 데이터를 제조사에 권고하여 발행되는 Reference Sheet에 기재하고자 한다. 본원에서는 2009년부터 부분적으로 BIO-RAD 정도관리 물질을 사용하여 2011년에는 일부 특정 항목을 제외한 대부분의 검사종목에 BIO-RAD 제 3자 정도관리물질을 사용하고 있다. 따라서 측정된 내부정도관리 데이터를 BIO-RAD사의 Unity Real Time program (version 1.0.9.27)을 이용하여 Acceptable Range를 설정하였다. BIO-RAD 정도관리 물질을 사용하는 약 50가지 검사종목의 20개 Point Data의 평균값, 표준편차, 변이계수를 구하여 측정kit별 Acceptable Range를 산출하였으며, 자동화 면역 측정기기인 Roche Elecsys/ E170/ cobas e Systems의 측정값과 비교하였다. 현재 시행하고 있는 외부정도관리 프로그램과 같이 BIO-RAD 정도관리 물질을 공통으로 사용하는 병원과 peer group을 설정하여 측정 kit별, 기기별 Acceptable Range를 제조사에 권고하여 Reference Sheet에 방사면역검사실에 적합한 Acceptable Range를 기재하여 검사결과의 객관성을 높이고 국내외적으로 방사면역측정법에 대한 인지도를 높이고자 한다.

• 대한핵의학회지
• /
• 제19권1호
• /
• pp.119-126
• /
• 1985

To evaluate the performance characteristics of CA 19-9 radioimmunoassay and the clinical significance of serum CA 19-9 assay in patients with malignancy, serum CA 19-9 levels were measured by radioimmunoassay using monoclonal antibody in 135 normal controls, 81 patients with various untreated malignancy, 9 patients of postoperative colon cancer without recurrence and 20 patients with benign gastrointestinal diseases, who visited Seoul National University Hospital from June, 1984 to March, 1985. The results were as follows; 1) The CA 19-9 radioimmunoassay was simple to perform and can be completed in one work day. And the between-assay reproducibility and the assay recovery were both excellent. 2) The mean serum CA 19-9 level in 135 normal controls was $8.4{\pm}4.2U/mL$. Normal upper limit of serum CA 19-9 was defined as 21.0 U/mL. 4 out of 135(3.0%) normal controls showed elevated CA 19-9 levels above the normal upper limit. 3) One out of 20(5.0%) patients with benign gastrointestinal diseases showed elevated serum CA 19-9 level above the normal upper limit. 4) In 81 patients with various' untreated malignancy, 41 patients(50.6%) showed elevated serum CA 19-9 levels. 66.7% of 18 patients with colorectal cancer, 100% of 2 patients with pancreatic cancer, 100% of 3 patients with common bile duct cancer, 47.1% of 17 patients with stomach cancer, 28.6% of 28 patients with hepatoma and 60.0% of 5 other gastrointestinal tract cancers showed elevated serum CA 19-9 levels. 5) The sensitivities of serum CA 19-9 related to resectability in colorectal and stomach cancer were 33.3% in resectable colorectal cancer, 83.3% in unresectable colorectal cancer, 41.7% in resectable stomach cancer, 60.0% in unresectable stomach cancer respectively. 6) The sensitivity of serum CA 19-9 in 9 patients of postoperative colorectal cancer without recurrence were 33.3% and significantly decreased compared with that of untreated colorectal cancer, 66.7% (p<0.05). 7) In patients with colorectal cancer, simultaneous measurement of serum CA 19-9 and serum CEA levels increased sensitivities. From above results, we concluded that serum CA 19-9 radioimmunoassay is simple to perform and reproducible, and is a useful indicator reflecting tumor extent and responses to the treatment in patients with malignancy.